Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents-Reference-Cited by-同舟云学术

Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents

Published:1987-06 Issue:6 Volume:31 Page:949-950
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Shungu D L,Nalin D R,Gilman R H,Gadebusch H H,Cerami A T,Gill C,Weissberger B

Abstract

Twenty-one strains of Campylobacter pylori (Campylobacter pyloridis) were tested for susceptibility to norfloxacin and other agents by the serial agar dilution method. Ampicillin (MIC for 90% of isolates [MIC90], 0.016 micrograms/ml) and famotidine (MIC90, greater than 1,024 micrograms/ml) were, respectively, the most and the least active of the agents tested. Norfloxacin (MIC90, 1 microgram/ml) and imipenem (MIC90, 0.125 micrograms/ml) were substantially active against this organism.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.31.6.949

Reference10 articles.

1. Relation of Campylobacter pyloridis to gastritis and peptic ulcer;Buck G. E.;J. Infect. Dis.,1986

2. Famotidine: pharmacodynamic and pharmokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome;Campoli-Richards D. M.;Drugs,1986

3. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis;Goodwin C. S.;J. Antimicrob. Chemother.,1986

4. Norfloxacin, a review of its antibacterial activity, pharmacokinetic properties and therapeutic use;Holmes B.;Drug Evaluation,1985

5. Antibiotic sensitivity of Campylobacter pyloridis;Kasper G.;Eur. J. Clin. Microbiol.,1985

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bismuth drugs as antimicrobial agents;Medicinal Chemistry;2020

2. FR145715, a novel histamine H2 receptor antagonist, with specific anti-Helicobacter pylori activities;European Journal of Pharmacology;1999-08

3. Peptic-Ulcer Disease in the Elderly;Clinics in Geriatric Medicine;1999-08

4. GASTROINTESTINAL DISEASES IN WOMEN;Medical Clinics of North America;1998-01

5. A Risk-Benefit Assessment of Drugs Used in the Eradication of Helicobacter pylori Infection;Drug Safety;1996-07